NASDAQ: FENC - Fennec Pharmaceuticals Inc.

Yield per half year: +3.15%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Fennec Pharmaceuticals Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2001-06-05
ISIN CA31447P1009
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.fennecpharma.com
Цена ао 10.89
Change price per day: -2.35% (6.37)
Change price per week: +3.84% (5.99)
Change price per month: +3.49% (6.01)
Change price per 3 month: +19.62% (5.2)
Change price per half year: +3.15% (6.03)
Change price per year: -44.56% (11.22)
Change price per 3 year: +47.74% (4.21)
Change price per 5 year: +7.06% (5.81)
Change price per 10 year: 0% (6.22)
Change price per year to date: +34.05% (4.64)
All parameters

Underestimation

Title Value Grade
P/S 13.46 1
P/BV -25.19 0
P/E 0 0
EV/EBITDA -23.65 0
Total: 2.88

Efficiency

Title Value Grade
ROA, % -61.13 0
ROE, % 141.31 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -2.38 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 3219999900 10
Yield Ebitda, % -4.89 0
Yield EPS, % -3.27 0
Total: 4.6
More

Institutions Volume Share, %
Southpoint Capital Advisors LP 4077214 15.04
Sonic Gp LLC 2407357 8.88
Solas Capital Management, LLC 1378513 5.09
Avoro Capital Advisors LLC 1200000 4.43
Vanguard Group Inc 1140063 4.21
DG Capital Management, LLC 1075634 3.97
Blackrock Inc. 934591 3.45
Harbert Fund Advisors, Inc. 466869 1.72
AIGH Capital Management LLC 329370 1.22
Gendell, Jeffrey L. 282478 1.04



Head Job title Payment Year of birth
Mr. Rostislav Raykov CEO & Director 885.07k 1976 (49 years)
Mr. Robert C. Andrade Chief Financial Officer 600.88k 1975 (50 years)
Mr. Lei Fang President of Pharstat Inc N/A
Mr. Mark Gowland Controller

Address: United States, Research Triangle Park. NC, 68 TW Alexander Drive - open in Google maps, open in Yandex maps
Website: https://www.fennecpharma.com